All News
Filter News
Found 236 articles
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look. -
Axcella announced it is initiating a new clinical program to study AXA1125 in patients with Long Covid. The trial will be conducted at the Oxford Centre for Clinical Magnetic Resonance Research.
-
Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID
10/26/2021
Axcella Therapeutics (Nasdaq: AXLA), today announced a new clinical program to investigate AXA1125 as a potential treatment for patients with Long COVID, a complex condition also known as Post COVID-19 Condition and Post-Acute Sequelae of COVID-19 (PASC).
-
Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021
10/19/2021
Axcella Therapeutics today announced that it will host a virtual R&D Day on Tuesday, October 26, 2021, at 10:00 a.m. ET.
-
CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO
10/13/2021
Curative Biotechnology, Inc. announced today that Dr. Catherine Sohn has joined the Company as a Special Advisor to the Board of Directors and the CEO.
-
Axcella Announces Upcoming Investor Conference Presentation - Oct 05, 2021
10/5/2021
Axcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced that management will be presenting at the H.C. Wainwright 5th Annual NASH Investor Conference.
-
Axcella Announces Upcoming Investor Conference Presentation - Sep 07, 2021
9/7/2021
Axcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced that management will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference.
-
Clinical Catch-Up: August 16-20
8/23/2021
It was another busy week in clinical trial news. Here’s a look. -
Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH
8/16/2021
Axcella today announced the publication of results from the company’s AXA1125-003 clinical study in The American Journal of Gastroenterology
-
Axcella Reports Second Quarter Financial Results and Provides Business Update
7/29/2021
Axcella, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions, announced financial results for the second quarter ended June 30, 2021 and provided a business update.
-
Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021
7/22/2021
Axcella today announced that it plans to report its second quarter 2021 financial results and other business updates on July 29, 2021. The company will host a conference call at 8:30 a.m. ET
-
Clinical Catch-Up: June 28-July 2
7/6/2021
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look. -
Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665
6/30/2021
Axcella Announces Initiation of EMMPOWER ℠ Phase 2 Clinical Trial of AXA1665
-
Tessera Therapeutics Appoints Industry Leaders Elliott Sigal & Mary Rozenman to Board of Directors
6/15/2021
Tessera Therapeutics announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the company’s Board of Directors.
-
Senda Biosciences Announces Closing of $98 Million Series B Financing
6/10/2021
Senda Biosciences, announced today the completion of a $55 million Series B extension financing, bringing its total Series B funding to $98 million and total funding raised to date to $143 million
-
Clinical Catch-Up: May 24-28
6/1/2021
Heading into the U.S. Memorial Day holiday weekend and the official start of summer, it was a moderately busy week for clinical trial news. Take a look. -
Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture
5/25/2021
Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, announced the closing of a Series C financing round totaling $88.9 million.
-
Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021
5/24/2021
Activity demonstrated across targeted biologies, including amino acid balance, ammonia handling, muscle function and neurocognition Presentation includes new subject-specific neurocognition and muscle function data
-
Clinical Catch-Up: May 10-14
5/17/2021
Although a quiet week for COVID-19-related clinical trial announcements, there were plenty of others. Read on for more information. -
Axcella Announces Initiation of EMMPACTSM Phase 2b Clinical Trial of AXA1125
5/11/2021
Axcella Announces Initiation of EMMPACT SM Phase 2b Clinical Trial of AXA1125 Initial clinical sites activated and patient screening underway Potential for AXA1125 to serve as a first-line therapy for patients with nonalcoholic steatohepatitis (NASH)